Information Provided By: 
Fly News Breaks for June 9, 2017
ENDP, IPXL
Jun 9, 2017 | 06:36 EDT
Deutsche Bank analyst Gregg Gilbert believes Impax (IPXL), as the company marketing the only generic of the old Opana ER, could benefit from the FDA's surprise request that Endo (ENDP) remove its reformulated Opana ER from the market. The analyst does not expect the FDA to take action against other oxymorphone products, including Impax's. Gilbert has a Buy rating on Impax with a $20 price target.
News For IPXL;ENDP From the Last 2 Days
There are no results for your query IPXL;ENDP
